Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 91 articles: HTML format Text format

Single Articles

May 2018
1. MAHLA RS
   KLRG1 Signaling is Contextual to Tuberculosis Immunity.
   J Infect Dis. 2018 May 28. pii: 5017236. doi: 10.1093.
   PubMed     Text format    
   
   
   
2. REICHLER MR, Khan A, Sterling TR, Zhao H, et al
   Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis.
   J Infect Dis. 2018 May 15. pii: 4996045. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
3. GUTHRIE JL, Delli Pizzi A, Roth D, Kong C, et al
   Genotyping and Whole Genome Sequencing to Identify Tuberculosis Transmission to Pediatric Patients in British Columbia, Canada, 2005-2014.
   J Infect Dis. 2018 May 11. pii: 4995040. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   April 2018
4. MILLER AC, Livchits V, Ahmad Khan F, Atwood S, et al
   Turning off the tap: Using the FAST approach to stop the spread of drug-resistant tuberculosis in Russian Federation.
   J Infect Dis. 2018 Apr 5. pii: 4961495. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
5. LACHMANDAS E, Rios-Miguel AB, Koeken VACM, van der Pasch E, et al
   Tissue metabolic changes drive cytokine responses to Mycobacterium tuberculosis.
   J Infect Dis. 2018 Apr 3. pii: 4959339. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   March 2018
6. URBANOWSKI ME, Ihms EA, Bigelow K, Kubler A, et al
   Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction.
   J Infect Dis. 2018 Mar 15. pii: 4936447. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
7. MURRAY LW, Satti I, Meyerowitz J, Jones M, et al
   Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis-Specific T-Cell Responses.
   J Infect Dis. 2018 Mar 13. pii: 4932783. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   February 2018
8. AGARWAL S, Tiwari P, Deep A, Kidwai S, et al
   System wide analysis unravels differential regulation and in vivo essentiality of VapBC TA systems from Mycobacterium tuberculosis.
   J Infect Dis. 2018 Feb 24. pii: 4909395. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
9. REECE ST, Vogelzang A, Tornack J, Bauer W, et al
   Mycobacterium tuberculosis-Infected Hematopoietic Stem and Progenitor Cells Unable to Express Inducible Nitric Oxide Synthase Propagate Tuberculosis in Mice.
   J Infect Dis. 2018 Feb 17. pii: 4869967. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
10. CHUNG YT, Pasquinelli V, Jurado JO, Wang X, et al
    Elevated cyclic AMP Inhibits Mycobacterium tuberculosis-stimulated T cell IFN-gamma Secretion through type I Protein Kinase A.
    J Infect Dis. 2018 Feb 8. pii: 4845549. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. KURODA MJ, Sugimoto C, Cai Y, Merino KM, et al
    High Turnover of Tissue Macrophages Contributes to Tuberculosis Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    J Infect Dis. 2018 Feb 8. pii: 4843840. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
12. KHAN N, Divangahi M
    Mycobacterium tuberculosis and HIV Coinfection Brings Fire and Fury to Macrophages.
    J Infect Dis. 2018 Feb 8. pii: 4843841. doi: 10.1093.
    PubMed     Text format    
    
    
    January 2018
13. PAIDIPALLY P, Tripathi D, Van A, Radhakrishnan RK, et al
    IL-21 regulates NK cell responses during Mycobacterium tuberculosis infection.
    J Infect Dis. 2018 Jan 30. pii: 4829454. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
14. HU Z, Zhao HM, Li CL, Liu XH, et al
    The role of KLRG1 in human CD4+ T cell immunity against tuberculosis.
    J Infect Dis. 2018 Jan 24. pii: 4823593. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. THOMPSON EG, Shankar S, Gideon HP, Braun J, et al
    Blood RNA signatures prospectively discriminate controllers from progressors early after low-dose M. tuberculosis infection of cynomolgus macaques.
    J Infect Dis. 2018 Jan 8. pii: 4792952. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    December 2017
16. ZHENG R, Liu H, Zhou Y, Yan D, et al
    Notch4 Negatively Regulates the Inflammatory Response to Mycobacterium tuberculosis Infection by Inhibiting TAK1 Activation.
    J Infect Dis. 2017 Dec 8. pii: 4712145. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    November 2017
17. GARFIN C, Mantala M, Yadav R, Hanson CL, et al
    Using Patient Pathway Analysis to Design Patient-centered Referral Networks for Diagnosis and Treatment of Tuberculosis: The Case of the Philippines.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
18. HANSON C, Osberg M, Brown J, Durham G, et al
    Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
19. HANSON CL, Osberg M, Brown J, Durham G, et al
    Conducting Patient-Pathway Analysis to Inform Programming of Tuberculosis Services: Methods.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
20. MASINI E, Hanson C, Ogoro J, Brown J, et al
    Using Patient-Pathway Analysis to Inform a Differentiated Program Response to Tuberculosis: The Case of Kenya.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
21. FATIMA R, Haq MU, Yaqoob A, Mahmood N, et al
    Delivering Patient-Centered Care in a Fragile State: Using Patient-Pathway Analysis to Understand Tuberculosis-Related Care Seeking in Pakistan.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
22. SURYA A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, et al
    Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public-Private Collaboration.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
23. FEKADU L, Hanson C, Osberg M, Makayova J, et al
    Increasing Access to Tuberculosis Services in Ethiopia: Findings From a Patient-Pathway Analysis.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
24. SISMANIDIS C, Shete PB, Lienhardt C, Floyd K, et al
    Harnessing the Power of Data to Guide Local Action and End Tuberculosis.
    J Infect Dis. 2017;216.
    PubMed     Text format    
    
    
    
25. REID MJA, Goosby E
    Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
    J Infect Dis. 2017;216.
    PubMed     Text format    
    
    
    
26. CHIN DP, Hanson CL
    Finding the Missing Tuberculosis Patients.
    J Infect Dis. 2017;216.
    PubMed     Text format    
    
    
    
27. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
28. CHURCHYARD G, Kim P, Shah NS, Rustomjee R, et al
    What We Know About Tuberculosis Transmission: An Overview.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
29. TURNER RD, Chiu C, Churchyard GJ, Esmail H, et al
    Tuberculosis Infectiousness and Host Susceptibility.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
30. MATHEMA B, Andrews JR, Cohen T, Borgdorff MW, et al
    Drivers of Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
31. AULD SC, Kasmar AG, Dowdy DW, Mathema B, et al
    Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
32. DOWDY DW, Grant AD, Dheda K, Nardell E, et al
    Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
    
33. SHAH NS, Kim P, Kana BD, Rustomjee R, et al
    Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format    
    
    
    
34. SALVATORE PP, Proano A, Kendall EA, Gilman RH, et al
    Linking individual natural history to population outcomes in tuberculosis.
    J Infect Dis. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    October 2017
35. AGORO R, Benmerzoug S, Rose S, Bouyer M, et al
    An Iron-Rich Diet Decreases the Mycobacterial Burden and Correlates With Hepcidin Upregulation, Lower Levels of Proinflammatory Mediators, and Increased T-Cell Recruitment in a Model of Mycobacterium bovis Bacille Calmette-Guerin Infection.
    J Infect Dis. 2017;216:907-918.
    PubMed     Text format     Abstract available
    
    
    
36. BUNJUN R, Riou C, Soares AP, Thawer N, et al
    Effect of HIV on the frequency and number of Mycobacterium tuberculosis-specific CD4+ T cells in blood and the airways in latent tuberculosis infection.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    September 2017
37. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    PubMed     Text format     Abstract available
    
    
    August 2017
38. SINGH V, Prakhar P, Rajmani RS, Mahadik K, et al
    Histone Methyltransferase SET8 Epigenetically Reprograms Host Immune Responses to Assist Mycobacterial Survival.
    J Infect Dis. 2017;216:477-488.
    PubMed     Text format     Abstract available
    
    
    June 2017
39. FOLKVARDSEN DB, Norman A, Andersen AB, Rasmussen EM, et al
    Genomic epidemiology of a major Mycobacterium tuberculosis outbreak: Retrospective cohort study in a low incidence setting using sparse time-series sampling.
    J Infect Dis. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
40. GUPTA S, Cheung L, Pokkali S, Winglee K, et al
    Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
    J Infect Dis. 2017;215:1883-1887.
    PubMed     Text format     Abstract available
    
    
    May 2017
41. YAO Y, Lai R, Afkhami S, Haddadi S, et al
    A novel virus-vectored respiratory mucosal vaccine enhances anti-tuberculosis immunity in a humanized model system.
    J Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
42. ANTHONY RM
    Sputum microscopy and tuberculosis infectiousness.
    J Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    
    
    
    
43. DATTA S, Sherman JM, Tovar MA, Bravard MA, et al
    Sputum microscopy with fluorescein diacetate predicts tuberculosis infectiousness.
    J Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    April 2017
44. THUONG NTT, Heemskerk D, Tram TTB, Thao LTP, et al
    Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    March 2017
45. OEHLERS SH, Cronan MR, Beerman RW, Johnson MG, et al
    Infection-Induced Vascular Permeability Aids Mycobacterial Growth.
    J Infect Dis. 2017;215:813-817.
    PubMed     Text format     Abstract available
    
    
    February 2017
46. HALLIDAY A, Whitworth H, Hermagild Kottoor S, Niazi U, et al
    Stratification of latent tuberculosis infection by cellular immune profiling.
    J Infect Dis. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
47. SHEN H, Gu J, Xiao H, Liang S, et al
    Selective Destruction of Interleukin 23-Induced Expansion of a Major Antigen-Specific gammadelta T-Cell Subset in Patients With Tuberculosis.
    J Infect Dis. 2017;215:420-430.
    PubMed     Text format     Abstract available
    
    
    January 2017
48. CLARK S, Lanni F, Marinova D, Rayner E, et al
    Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    J Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
49. JANSSEN S, Schutz C, Ward AM, Huson MA, et al
    Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study.
    J Infect Dis. 2017;215:247-258.
    PubMed     Text format     Abstract available
    
    
    December 2016
50. MARAIS S, Lai RP, Wilkinson KA, Meintjes G, et al
    Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    October 2016
51. JEYANATHAN M, Damjanovic D, Yao Y, Bramson J, et al
    Induction of an immune protective T cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in man.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
52. MARTINEZ N, Ketheesan N, West K, Vallerskog T, et al
    Impaired Recognition of Mycobacterium tuberculosis by Alveolar Macrophages from Diabetic Mice.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
53. SINGH DK, Dwivedi VP, Ranganathan A, Bishai WR, et al
    Blockade of the Kv1.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
54. SCHLUGER NW
    Host-pathogen interactions in tuberculosis: the evolving story.
    J Infect Dis. 2016.
    PubMed     Text format    
    
    
    
55. WALTER ND, de Jong BC, Garcia BJ, Dolganov GM, et al
    Adaptation of M. tuberculosis to impaired host immunity in HIV-infected patients.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
56. CHEN L, Zhang J, Zhang H
    Heteroresistance of Mycobacterium tuberculosis strains may be associated more strongly with poor treatment outcomes than within-host heterogeneity of M. tuberculosis infection.
    J Infect Dis. 2016.
    PubMed     Text format    
    
    
    
57. HORNE DJ, Graustein AD, Shah JA, Peterson G, et al
    Human ULK1 Variation and Susceptibility to Mycobacterium tuberculosis Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
58. DINARDO AR, Mace EM, Lesteberg K, Cirillo JD, et al
    Schistosome Soluble Egg Antigen Decreases Mycobacterium tuberculosis-Specific CD4+ T-Cell Effector Function With Concomitant Arrest of Macrophage Phago-Lysosome Maturation.
    J Infect Dis. 2016;214:479-88.
    PubMed     Text format     Abstract available
    
    
    
59. AHSAN F, Moura-Alves P, Guhlich-Bornhof U, Klemm M, et al
    Role of Interleukin 36gamma in Host Defense Against Tuberculosis.
    J Infect Dis. 2016;214:464-74.
    PubMed     Text format     Abstract available
    
    
    July 2016
60. DIEDRICH CR, O'Hern J, Gutierrez MG, Allie N, et al
    Relationship between HIV-1 co-infection, IL-10, and M. tuberculosis in human lymph node granulomas.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
61. YANG HJ, Kong Y, Cheng Y, Janagama H, et al
    Real-Time Imaging of Mycobacterium tuberculosis Using a Novel Near-Infrared Fluorescent Substrate.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    May 2016
62. SCRIBA TJ, Kaufmann SH, Lambert PH, Sanicas M, et al
    Vaccination against tuberculosis with whole cell mycobacterial vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
63. SHEPELKOVA G, Evstifeev V, Majorov K, Bocharova I, et al
    Therapeutic effect of recombinant mutated IL-11 in the mouse model of tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    April 2016
64. PRADOS-ROSALES R, Carreno LJ, Weinrick B, Batista-Gonzalez A, et al
    The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    
65. JOLOBA M, Mwangi C, Alexander H, Nadunga D, et al
    Strengthening the Tuberculosis Specimen Referral Network in Uganda: The Role of Public-Private Partnerships.
    J Infect Dis. 2016;213 Suppl 2:S41-6.
    PubMed     Text format     Abstract available
    
    
    
66. JABOT-HANIN F, Cobat A, Feinberg J, Grange G, et al
    Major Loci on Chromosomes 8q and 3q Control Interferon gamma Production Triggered by Bacillus Calmette-Guerin and 6-kDa Early Secretory Antigen Target, Respectively, in Various Populations.
    J Infect Dis. 2016;213:1173-9.
    PubMed     Text format     Abstract available
    
    
    March 2016
67. MINHINNICK A, Harris S, Wilkie M, Peter J, et al
    Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    J Infect Dis. 2016;213:824-30.
    PubMed     Text format     Abstract available
    
    
    January 2016
68. COHEN T, Chindelevitch L, Misra R, Kempner ME, et al
    Within-host heterogeneity of M. tuberculosis infection is associated with poor early treatment response: a prospective cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available
    
    
    November 2015
69. BOILLAT-BLANCO N, Ramaiya KL, Mganga M, Minja LT, et al
    Transient Hyperglycemia in Patients with Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
70. ELLIOTT TO, Owolabi O, Donkor S, Kampmann B, et al
    Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression.
    J Infect Dis. 2015;212:1469-79.
    PubMed     Text format     Abstract available
    
    
    October 2015
71. AGUILO N, Alvarez-Arguedas S, Uranga S, Marinova D, et al
    Pulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
72. KUMAR NP, Moideen K, George PJ, Dolla C, et al
    Impaired cytokine but enhanced cytotoxic marker expression in Mycobacterium tuberculosis - induced CD8+ T cells in Type 2 diabetic individuals with latent tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    September 2015
73. KUBLER A, Larsson C, Luna B, Andrade BB, et al
    Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
74. KASPROWICZ VO, Cheng TY, Ndung'u T, Sunpath H, et al
    HIV disrupts human T cells that target mycobacterial glycolipids.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
75. CLIFF JM, Cho JE, Lee JS, Ronacher K, et al
    Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    July 2015
76. ZELNER JL, Murray MB, Becerra MC, Galea J, et al
    Identifying hotspots of multidrug resistant tuberculosis transmission using spatial and molecular genetic data.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
77. ARMITAGE AE, Moran E
    HIV-associated tuberculosis: does the iron-regulatory hormone hepcidin connect anemia with poor prognosis?
    J Infect Dis. 2015.
    PubMed     Text format    
    
    
    
78. KERKHOFF AD, Meintjes G, Burton R, Vogt M, et al
    Relationship between blood concentrations of hepcidin and anaemia severity, mycobacterial burden and mortality in patients with HIV-associated tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
79. PASIPANODYA J, Srivastava S, Gumbo T
    Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.
    J Infect Dis. 2015;212:166-7.
    PubMed     Text format    
    
    
    June 2015
80. SALVATORE PP, Becerra MC, Zur Wiesch PA, Hinkley T, et al
    Fitness Costs of Drug-resistance Mutations in Multidrug Resistant M. tuberculosis: A Household-based Case-control Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    
81. NUERMBERGER E, Hanna D
    Assessing the landscape of tools and approaches for novel tuberculosis regimen development.
    J Infect Dis. 2015;211 Suppl 3:S81-2.
    PubMed     Text format    
    
    
    
82. MCILLERON H, Abdel-Rahman S, Dave JA, Blockman M, et al
    Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.
    J Infect Dis. 2015;211 Suppl 3:S115-25.
    PubMed     Text format     Abstract available
    
    
    
83. GUMBO T, Angulo-Barturen I, Ferrer-Bazaga S
    Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    J Infect Dis. 2015;211 Suppl 3:S96-S106.
    PubMed     Text format     Abstract available
    
    
    
84. GUMBO T, Lenaerts AJ, Hanna D, Romero K, et al
    Nonclinical models for antituberculosis drug development: a landscape analysis.
    J Infect Dis. 2015;211 Suppl 3:S83-95.
    PubMed     Text format     Abstract available
    
    
    
85. SAHASRABUDHE V, Zhu T, Vaz A, Tse S, et al
    Drug metabolism and drug interactions: potential application to antituberculosis drugs.
    J Infect Dis. 2015;211 Suppl 3:S107-14.
    PubMed     Text format     Abstract available
    
    
    
86. AICHELBURG MC
    Reply to Schepisi et al.
    J Infect Dis. 2015;211:1854.
    PubMed     Text format    
    
    
    May 2015
87. PAN SJ, Tapley A, Adamson J, Little T, et al
    Biomarkers for tuberculosis based on secreted, species-specific, bacterial small molecules.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available
    
    
    April 2015
88. DENKINGER CM, Dolinger D, Schito M, Wells W, et al
    Target product profile of a molecular drug-susceptibility test for use in microscopy centers.
    J Infect Dis. 2015;211 Suppl 2:S39-49.
    PubMed     Text format     Abstract available
    
    
    January 2015
89. SANE SCHEPISI M, Parracino MP, Mammone A, Bellagamba R, et al
    Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country.
    J Infect Dis. 2015.
    PubMed     Text format    
    
    
    December 2014
90. SAIGA H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, et al
    The recombinant BCG DeltaureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation.
    J Infect Dis. 2014.
    PubMed     Text format     Abstract available
    
    
    November 2014
91. MIDDELKOOP K, Mathema B, Whitelaw A, Bekker LG, et al
    Reply to Yates et al.
    J Infect Dis. 2014.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: